JHP
NVO

James Hambro & Partners’s Novo Nordisk NVO Stock Holding History

James Hambro & Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,090
Closed -$1.12M – 52
2025
Q1 		$1.12M Hold
16,090
– – 0.05% 30
2024
Q4 		$1.38M Hold
16,090
– – 0.05% 30
2024
Q3 		$1.92M Hold
16,090
– – 0.08% 29
2024
Q2 		$2.3M Hold
16,090
– – 0.11% 28
2024
Q1 		$2.07M Buy
16,090
+1,000
+7% +$119K 0.1% 30
2023
Q4 		$1.56M Buy
+15,090
New +$1.49M 0.08% 31

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

James Hambro & Partners's NVO Position: Q2 2025 in Review

James Hambro & Partners sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 16,090 shares — an estimated $1.12M sold.

James Hambro & Partners first reported a position in NVO in Q4 2023 and held it in 6 quarters. The position peaked at $2.3M in Q2 2024. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • James Hambro & Partners reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • James Hambro & Partners sold 16,090 Novo Nordisk shares in Q2 2025, an estimated $1.12M.
  • James Hambro & Partners first reported a position in Novo Nordisk in Q4 2023 and held it in 6 quarters.
  • James Hambro & Partners's Novo Nordisk position peaked at $2.3M in Q2 2024.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on James Hambro & Partners's 13F filing for Q2 2025, filed 17 Jul 2025.